*Sponsored
Krypton Street Initiates Coverage On Autonomix Medical, Inc. (NASDAQ: AMIX) Starting This Morning—Friday, June 27, 2025
Here's What We Can Tell You About (AMIX) — So Far…
Analyst Targets: With One That Suggests Over 1,300% Upside Potential
From Current Levels
Tiny Float: Fewer Than 2.2M Shares Could Set The Stage For Big Swing Potential If Demand Begins To Shift.
$100B Target Area: Focused On Pain, Nerve Signals, And Stimulation
Pull Up (AMIX) While It's Still Early
June 27, 2025 Coverage Begins | See Why (AMIX) is Lighting Up Our Radar This Morning Dear Reader, Every potential breakout profile starts the same way—under the radar, until something shifts. Right now, we're seeing signals in a little-known medtech name with a low float and big upside potential according to recent analyst coverage. It's Autonomix Medical, Inc. (NASDAQ: AMIX)—and it's lighting up our radar ahead of the opening bell. According to MarketWatch, (AMIX) has fewer than 2.2M shares in its public float—placing it among the tightest floats currently listed on Nasdaq. When a company has a float this small, it doesn't take much for it to see big swing potential, when demand begins to shift. Just this month, two institutional analysts released coverage with head-turning upside targets: - On June 12, Maxim Group's Anthony Vendetti reiterated coverage on (AMIX) with a $5 target, based on the strength of its early clinical data and medical platform. Which suggests over 290% upside potential from recent levels.
- Then yesterday, on June 26, Jeffrey Cohen of Ladenburg Thalmann raised the bar dramatically—publishing a note assigning an $18 target. From where (AMIX) began the day, this suggests more than 1,300% upside potential.
At the same time, RSI readings across the 9, 14, and 20-day timeframes are hovering in the mid-30s—a technical zone that has historically signaled early-stage momentum for potential trend reversals. Keep reading to see why (AMIX) has our attention now—and what may come next. Autonomix Medical, Inc. (NASDAQ: AMIX): Precision-Guided
Innovation in Cancer Pain Care (AMIX) is working to transform how pain is addressed in some of the most difficult medical cases—starting with advanced cancers like pancreatic. Backed by strong early clinical results, a growing patent portfolio, and a leadership team with a proven track record, Autonomix is developing a new kind of treatment system that goes far beyond today's standard methods. At the center of their platform is a specialized device powered by a proprietary microchip—built to detect and interpret nerve activity with remarkable accuracy. This chip is small enough to get close to the source of pain and smart enough to guide real-time treatment, allowing doctors to pinpoint overactive nerves, treat them directly, and confirm success in one seamless procedure. 
Unlike current techniques that rely on indirect targeting or blind ablation, Autonomix's system gives physicians real-time feedback—offering greater confidence and control during treatment. This targeted approach may help reduce complications, lower opioid use, and open doors to broader nerve-related care. Tackling a Critical Pain Challenge
Pancreatic cancer is one of the most aggressive forms of cancer, and for many patients, pain becomes overwhelming and difficult to manage. In Autonomix's first-in-human clinical trial, the company treated 20 patients facing this exact issue—and the results were significant. - 100% of patients treated through one specific access point responded to the procedure
- Pain relief began in as little as 24 hours
- After 4–6 weeks, 73% of responders no longer needed opioids
- No serious complications related to the device or the procedure were reported
These outcomes point to more than just symptom relief—they highlight the potential for a safer, more targeted way to manage pain when few other options exist. A Smarter, More Targeted Platform
What sets Autonomix apart is how their system works. It doesn't rely on traditional approaches that often treat the entire area or require broad interventions. Instead, the company's platform uses a combination of real-time feedback and precision tools to treat only the nerves causing the issue—while confirming during the procedure that the treatment is working. This is a smarter, more focused method of pain management that may also be applied to other serious conditions involving nerve activity. What's Next: Clinical Expansion Underway Following the success of its first trial, Autonomix is launching a second phase—expanding its platform to include a broader range of cancers that also cause intense nerve-driven pain. These include earlier-stage pancreatic cancer, as well as liver, bile duct, and gall bladder cancers. This expanded study is expected to begin in Q2 2025 and could significantly increase the clinical scope of Autonomix's system. The company remains on track for a 2026 FDA submission, with a long-term path toward broader regulatory clearance. With breakthrough technology, early clinical traction, and a clear expansion plan, Autonomix is aiming to redefine how cancer pain is managed—and possibly much more. A Platform Built by Veterans
Autonomix isn't just betting on technology—it's backed by a leadership team with a track record of execution. CEO Brad Hauser previously led exits totaling over $3B, including a $550M acquisition by AbbVie and a $2.4B sale to Allergan. Other key executives and co-founders also bring deep medtech experience and have led companies through commercialization, regulatory approval, and large-scale acquisitions. With more than 120 issued and pending patents, Autonomix is working to secure a durable IP moat around its proprietary systems and signal-processing technologies. Recent Developments
Over the past several weeks, (AMIX) has released a series of updates that underscore both the momentum behind its clinical program and the growing institutional confidence in its proprietary platform. June 2025: Clinical Expansion Approved
Autonomix received Ethics Committee authorization to begin PoC 2, the next phase of its clinical program. This study expands beyond pancreatic cancer to include liver, bile duct, and gall bladder cancers—conditions tied to intense nerve-driven pain. With enrollment expected to begin soon, (AMIX) is now targeting a broader clinical field that could double its reach. May 2025: Key U.S. Patent Granted
In a major milestone, Autonomix was granted U.S. Patent No. 12,257,071, covering its real-time nerve-mapping and ablation technology. The patent protects innovations like embedded sensors, adaptive controls, and full-system integration—further strengthening (AMIX)'s edge in treating nerve-driven conditions with precision and minimal invasiveness. April–May 2025: Breakthrough Clinical Results
Autonomix shared strong results from its first human trial treating pancreatic cancer pain. 100% of targeted patients responded, with pain relief starting in 24 hours, and 73% off opioids by week six. These results confirmed both the safety and power of the company's "Sense, Treat, Verify" approach—and set the stage for its upcoming expansion into other high-need areas. Positioned for the Future
Autonomix is targeting a total combined market potential exceeding $100B, with focus areas spanning pain management, neurostimulation, and visceral nerve-related indications. Its minimally invasive system stands out in a field crowded by blind ablation procedures and signal-blind diagnostics. As new trials begin and technical progress continues, (AMIX) remains a name worth watching in the emerging class of neural-targeted precision therapies. 7 Reasons Why (AMIX) Is Topping Our Watchlist This Morning
—Friday, June 27, 2025….
See Company Presentation Deck Here 1. Analyst Targets: In June 2025, (AMIX) received analyst targets of $5 (Maxim Group, approx. 290% upside potential ) and $18 (Ladenburg Thalmann, approx. 1,306% upside potential)—pointing to strong institutional interest.
2. Tiny Public Float: With fewer than 2.2M shares in circulation, (AMIX) has the potential for big swings if demand begins to shift. 3. Oversold Technicals: RSI levels for (AMIX) have hovered in the mid-30s across multiple timeframes—a setup that has historically signaled early-stage momentum for potential trend reversals. 4. Trial Results Delivered: Early data from (AMIX)'s first-in-human study showed a 59.2% average reduction in pain and 73% of patients eliminating opioid use within 4–6 weeks. 5. Platform Expansion Underway: As of June 2025, (AMIX) secured approval to begin a follow-on clinical study targeting visceral cancers that could double its clinical reach. 6. Patent Momentum Building: A newly granted U.S. patent in May 2025 strengthened (AMIX)'s hold on its core catheter-based system, adding to a portfolio of 120+ issued and pending patents. 7. Targeting $100B Space: With focus areas across pain management, neurostimulation, and nerve-focused conditions, (AMIX) is positioned in segments exceeding $100B combined. Pull Up (AMIX) While It's Still Early
Keep in mind—(AMIX) has fewer than 2.2M shares in its public float. Add in recent analyst targets from Maxim Group ($5) and Ladenburg Thalmann ($18), reflecting approximately 290% and 1,306% upside potential, and we're looking at a situation that demands attention. Backed by real clinical data, fresh patent momentum, a next-phase trial now underway, and RSI levels which have historically signaled the potential for early-stage trend reversals—Autonomix Medical, Inc. (NASDAQ: AMIX) is positioning itself in a high-value space that could top $100B across pain management, neurostimulation, and nerve-targeted care. We have (AMIX) at the top of our screens right now. Pull up (AMIX) while it's still early. Keep an out for my next update—it could be hitting your inbox within the next 60 to 90 minutes. Sincerely,
Alex Ramsay
Co-Founder / Managing Editor Krypton Street Newsletter
| 
Tidak ada komentar:
Posting Komentar